Zhenxuan Ma

Mr. Zhenxuan Ma

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2017 in Molecules
Verified
Journal Article
Open access
PDF file
SSShan Su
Shan Su
ZMZhenxuan Ma
Zhenxuan Ma
CHChen Hua
Chen Hua
WLWeihua Li
Weihua Li
Lu LuLu Lu
Lu Lu
Shibo JiangShibo Jiang
Shibo Jiang
Peptides derived from the C-terminal heptad repeat (CHR) of human immunodeficiency virus type 1 (HIV-1) envelope protein transmembrane subunit gp41, such as T20 (enfuvirtide), can bind to the N-terminal heptad repeat (NHR) of gp41 and block six-helix bundle (6-HB) formation, thus inhibiting HIV-1 fusion with the target cell. However, clinical application of T20 is limited because of its low potency and genetic barrier to resistance. HP23, the shortest CHR peptide, exhibits better anti-HIV-1 activity than T20, but the HIV-1 strains with E49K mutations in gp41 will become resistant to it. Here, we modified HP23 by extending its C-terminal sequence using six amino acid residues (E6) and adding IDL (Ile-Asp-Leu) to the C-terminus of E6, which is expected to bind to the shallow pocket in the gp41 NHR N-terminal region. The newly designed peptide, designated HP23-E6-IDL, was about 2- to 16-fold more potent than HP23 against a broad spectrum of HIV-1 strains and more than 12-fold more effective against HIV-1 mutants resistant to HP23. These findings suggest that addition of an anchor–tail to the C-terminus of a CHR peptide will allow binding with the pocket in the gp41 NHR that may increase the peptide’s antiviral efficacy and its genetic barrier to resistance.

9 April 2022 in Journal of Viral Hepatitis
Verified
Journal Article
Closed access
ZMZhenxuan Ma
Zhenxuan Ma
YQYanli Qin
Yanli Qin
YJYidi Jia
Yidi Jia
YXYiran Xie
Yiran Xie
XQXun Qi
Xun Qi
JZJiming Zhang
Jiming Zhang

9 August 2025 in Virology Journal
Verified
Journal Article
Open access
SYSisi Yang
Sisi Yang
QYQiaofeng Ye
Qiaofeng Ye
YYYida Yang
Yida Yang
ZMZhenxuan Ma
Zhenxuan Ma
Background: Evaluation of liver fibrosis appears to be easily overlooked in the clinic for the chronic Hepatitis D. Herein, we determine the Clinical Impact of liver fibrosis among HBsAg-positive/Anti-HDV positive US general adults. Methods: Data were obtained from the National Health and Nutrition Examination Survey (NHANES) 1999–2020. Liver fibrosis was assessed by the Fibrosis-4 (FIB-4) and aspartate aminotransferase to platelet ratio index (APRI) score. To minimize confounding, propensity score matching (PSM) was applied to compare HBV/HDV-coinfected and HBV-monoinfected individuals. Results: Out of 107,622 NHANES adults, 54,550 were tested for HBsAg and Anti-HDV, of whom 214 were identified as HBsAg-positive only, 50 were identified as HBsAg-positive/Anti-HDV-positive with available data for FIB-4/APRI. Mean APRI scores were 0.26 for the Non-Viral Hepatitis (NVH) group, 0.37 for the HBV group, and 0.42 for the HBV + HDV group. Corresponding mean FIB-4 scores were 1.07, 1.34, and 1.58, respectively. After PSM, HDV-infected individuals exhibited significantly higher fibrosis scores compared to HBV-positive individuals. Conclusion: Hepatitis D is more severe than hepatitis B, with a higher propensity to progress to liver fibrosis. These findings highlight the importance of routine fibrosis screening in HBsAg-positive/anti-HDV-positive individuals to prevent advanced liver disease.

7 December 2022 in Canadian Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
PDF file
JZJiming Zhang
Jiming Zhang
HZHao-Xiang Zhu
Hao-Xiang Zhu
YGYifei Guo
Yifei Guo
ZMZhenxuan Ma
Zhenxuan Ma
XQXun Qi
Xun Qi
JZJiming Zhang
Jiming Zhang
Background. Nucleotide analogues (NTs) monotherapy may have a more significant effect on reducing hepatitis B surface antigen (HBsAg) than nucleoside analogues (NSs) due to their immunomodulatory function. However, this superiority remains unknown when combined with PEGylated interferon α (PegIFNα). Therefore, this study aimed to explore whether NTs have more significant antiviral effects than NSs in combination therapy with PegIFNα. Methods. Chronic hepatitis B (CHB) patients treated with PegIFNα plus nucleos(t)ide analogues (NAs) were retrospectively recruited. Efficacy and the predictors of hepatitis B surface antigen (HBsAg) reduction >1 log10 IU/mL after 48 weeks were analyzed. Results. A total of 95 patients were included and divided into the PegIFNα + NTs group and the PegIFNα + NSs group. Propensity score matching (PSM) was performed. The PegIFNα + NTs group had a greater reduction of HBsAg (−3.52 vs. −2.33 log10 IU/mL, ) and a higher proportion of patients with HBsAg reduction >1 log10 IU/mL (100.0% vs. 72.2%, ) even after PSM. However, HBsAg and hepatitis B e-antigen (HBeAg) loss rates, HBeAg seroconversion rates, degree of HBeAg and hepatitis B virus (HBV) DNA decline, HBV DNA undetectable rates, and alanine aminotransferase (ALT) normalization rates showed no significant differences. Subgroup analyses showed the difference in the reduction of HBsAg was particularly evident in HBeAg-positive and the “add-on” subgroups. PegIFNα plus NTs (OR = 36.667, 95% CI = 3.837–350.384) was an independent predictor for HBsAg reduction >1 log10 IU/mL after 48 weeks. Conclusion. This study suggests that PegIFNα plus NTs may lead to more HBsAg reduction, especially in HBeAg-positive and “add-on” patients.

18 June 2025 in Liver International
Verified
Journal Article
Closed access
SYSisi Yang
Sisi Yang
QYQiaofeng Ye
Qiaofeng Ye
ZMZhenxuan Ma
Zhenxuan Ma

29 July 2026 in The Kaohsiung Journal of Medical Sciences
Verified
Journal Article
Open access
PDF file
YCYing‐Lun Chen
Ying‐Lun Chen
ZMZhenxuan Ma
Zhenxuan Ma
Click on the article title to read more.